论文信息 - An open-label trial of JAK 1/2 blockade in progressive IFIH1-associated neuroinflammation

An open-label trial of JAK 1/2 blockade in progressive IFIH1-associated neuroinflammation

IFIH1 gain-of-function causes a spectrum of neuroinflammatory phenotypes associated with enhanced type I interferon production and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway activation.1,2 Patients most often present in infancy, variably exhibiting spasticity, dystonia, seizures, and acquired microcephaly. We report the use of ruxolitinib, a JAK 1/2 blocker, in the treatment of early-onset, progressive neurologic disease due to an IFIH1 mutation.

[1] F. Rieux-Laucat,et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. , 2016, The Journal of allergy and clinical immunology.

[2] Y. Crow,et al. Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview , 2016, The Journal of experimental medicine.

[3] E. Tantsis,et al. B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination , 2016, PloS one.

[4] O. Ohara,et al. Aicardi-Goutières syndrome is caused by IFIH1 mutations. , 2014, American journal of human genetics.

[5] L. Lagae,et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling , 2014, Nature Genetics.

[6] A. Vanderver,et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study , 2013, The Lancet Neurology.

[7] A. Tefferi,et al. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. , 2011, Mayo Clinic proceedings.